Sino Biopharmaceutical AI Stock Analysis
Sino Biopharmaceutical (SMZ1) AI Stock Analysis
Sino Biopharmaceutical
(Frankfurt:SMZ1)
No summary available
Sino Biopharmaceutical (SMZ1) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 11.84B
- Dividend Yield
- 1.99%
- Average Volume (3M)
- 2,748
- Price to Earnings (P/E)
- 34.9
- Beta (1Y)
- 0.03
- Revenue Growth
- 6.55%
- EPS Growth
- -35.88%
- Country
- Germany
- Employees
- 22,838
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicin...
Sino Biopharmaceutical Peers Comparison
Overall Rating
HK:153082Outperform
HK:180163Neutral
HK:269657Neutral
HK:992644.7Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | HKD 35.19B | 3.54 | 30.16% | 1.80% | 101.73% | 249.15% | |
| 63Neutral | HKD 149.97B | 102.93 | 6.06% | ― | 42.64% | 9.67% | |
| 57Neutral | HKD 23.93B | 23.43 | 20.41% | ― | 32.63% | 8.74% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | HKD 58.26B | -50.54 | -10.86% | ― | 42.47% | -15.80% | |
| 41Neutral | HKD 27.62B | -63.54 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:SMZ1 | Sino Biopharmaceutical | 0.62 | -0.14 | -18.35% | |
| HK:1801 | Innovent Biologics | 85.80 | -3.85 | -4.29% | |
| HK:1530 | 3SBio, Inc. | 13.86 | -17.85 | -56.29% | |
| HK:9926 | Akeso, Inc. | 61.90 | -49.90 | -44.63% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 14.11 | -10.15 | -41.84% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 43.88 | -20.57 | -31.92% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
